Anna Mira Lubis, Evy Yunihastuti, Agnes Stephanie Harahap, Gabriella Anindyah, Amirah Yasmin, Matdoan Rifkiah Aisyah
{"title":"甲磺酸伊马替尼治疗艾滋病毒感染者皮质类固醇难治性特发性嗜酸性粒细胞增多综合征的完全血流变反应:1例报告。","authors":"Anna Mira Lubis, Evy Yunihastuti, Agnes Stephanie Harahap, Gabriella Anindyah, Amirah Yasmin, Matdoan Rifkiah Aisyah","doi":"10.1177/09564624251338593","DOIUrl":null,"url":null,"abstract":"<p><p>We present a case of a 38-year-old person living with HIV (PLHIV) diagnosed with refractory idiopathic hypereosinophilic syndrome (HES). His initial symptoms were pruritic skin rash, dry cough, and diarrhea. The patient was unresponsive to corticosteroid as a first-line therapy. Subsequent treatment with Imatinib mesylate 100 mg per day resulted in excellent and sustained hematological and clinical response, with a likely molecular response as well.</p>","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624251338593"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Complete hematological response with imatinib mesylate in a corticosteroid refractory idiopathic hypereosinophilic syndrome in person living with HIV: A case report.\",\"authors\":\"Anna Mira Lubis, Evy Yunihastuti, Agnes Stephanie Harahap, Gabriella Anindyah, Amirah Yasmin, Matdoan Rifkiah Aisyah\",\"doi\":\"10.1177/09564624251338593\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We present a case of a 38-year-old person living with HIV (PLHIV) diagnosed with refractory idiopathic hypereosinophilic syndrome (HES). His initial symptoms were pruritic skin rash, dry cough, and diarrhea. The patient was unresponsive to corticosteroid as a first-line therapy. Subsequent treatment with Imatinib mesylate 100 mg per day resulted in excellent and sustained hematological and clinical response, with a likely molecular response as well.</p>\",\"PeriodicalId\":14408,\"journal\":{\"name\":\"International Journal of STD & AIDS\",\"volume\":\" \",\"pages\":\"9564624251338593\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of STD & AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09564624251338593\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of STD & AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09564624251338593","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Complete hematological response with imatinib mesylate in a corticosteroid refractory idiopathic hypereosinophilic syndrome in person living with HIV: A case report.
We present a case of a 38-year-old person living with HIV (PLHIV) diagnosed with refractory idiopathic hypereosinophilic syndrome (HES). His initial symptoms were pruritic skin rash, dry cough, and diarrhea. The patient was unresponsive to corticosteroid as a first-line therapy. Subsequent treatment with Imatinib mesylate 100 mg per day resulted in excellent and sustained hematological and clinical response, with a likely molecular response as well.
期刊介绍:
The International Journal of STD & AIDS provides a clinically oriented forum for investigating and treating sexually transmissible infections, HIV and AIDS. Publishing original research and practical papers, the journal contains in-depth review articles, short papers, case reports, audit reports, CPD papers and a lively correspondence column. This journal is a member of the Committee on Publication Ethics (COPE).